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Outpatients with CLBP who received at least one acupuncture session in a Korean 
Medicine clinic during the study period were included and followed up for 3 months. 
All patients received regular acupuncture treatments in accordance with the doc-
tors’ discretion. The clinical effects were measured by condition-specific outcomes 
and preference-based outcome. In terms of cost analysis, the cumulative resource 
use for direct medical costs at each research clinic during the study period and direct 
patient data using the self-reported health care utilization questionnaires were 
used. Results: A total of 105 patients were finally analyzed. Significant improve-
ments in condition-specific and preference-based measures were observed after 
acupuncture treatment. An average of approximately $134 per patient was reported 
for direct medical costs in each clinic for one month (8.5 sessions) and $213 for three 
months (13.5 sessions). Other medical expenses related to CLBP were reduced dur-
ing this period. ConClusions: Acupuncture to manage CLBP in general clinical 
practice in Korea, inexpensively improved pain, functional disability, and quality 
of life. The study results are meaningful and consistent with the results of previous 
randomized controlled trials performed in other European countries. A large-scale 
prospective cohort or registry based on practice may be helpful to strengthen the 
evidence of the cost-effectiveness of acupuncture.
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objeCtives: In the treatment of psoriatic arthritis (PsA), switching between alter-
native biologic treatments is common. A cost-effectiveness model was developed 
to assess the impact of placing apremilast, a new oral treatment, prior to biolog-
ics in PsA patients who had failed traditional DMARD therapy, from a U.S. payer 
perspective. Methods: A lifetime Markov state transition cohort model was 
developed which compared two treatment sequences in the base-case: apremi-
last followed by adalimumab followed by etanercept vs. adalimumab followed 
by etanercept. Patients who failed etanercept were assumed to receive best sup-
portive care (BSC) as the last line of treatment. Response to therapy was assessed 
using the Psoriatic Arthritis Response Criteria (PsARC) at the end of the clinical 
trial periods, ranging from 12 to 16 weeks depending on drug. Non-responders 
moved to the next line of therapy. A 16.5% annual drop-out rate was assumed for 
each drug. Treatment efficacy inputs were obtained from a meta-analysis and 
trial results. Drug costs were sourced from 2013 WAC prices, and a 3% annual dis-
count rate was applied to costs and QALYs. Apremilast was assumed to be priced 
at a discount to biologics. Utilities were estimated from HAQ and PASI response 
using a previously published regression equation. Results: The apremilast arm 
provided an additional 2.53 years with a PsARC response and an additional 0.78 
QALYs. Total time spent on the biologics was reduced by 0.34 years and time 
spent in BSC was reduced by 2.85 years. Under base-case assumptions, placing 
apremilast before biologics was found to be the dominant strategy (costs reduced 
by $28,794). Sensitivity analyses indicated that several parameters (e.g. cost of BSC 
and baseline utility) influence the ICER. Similar results were obtained with dif-
ferent biologic drugs in the sequence. ConClusions: Placing apremilast before 
biologics is a cost-saving strategy in the treatment of PsA.
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objeCtives: Osteoarthritis generally affects the joint functions of elderly patients 
causing significant pain and burden. There is no cure for osteoarthritis and treat-
ments tend to aim to alleviate pain and slow the progression of the disease. This 
study estimates the cost-effectiveness of celecoxib for treatment of osteoarthritis in 
China. Methods: The National Institute for Health and Clinical Excellence (NICE) 
developed a health economic model that was adapted to update the relative risks 
of adverse events using data from the CONDOR trial. This study localized the model 
to treatment patterns and costs in China. Comparators included celecoxib and 
diclofenac + PPI. The relative risks for adverse events were taken from the CONDOR 
trial. The base case patient was 55 years old. Treatment cycles were set to 3 months 
and the model ran for 180 cycles. Effectiveness was measured in quality-adjusted 
life years (QALYs). Costs and QALYs were discounted annually at 4.75%. Costs were 
reported in 2013 USD (1 USD = 6.07 RMB). Results: For celecoxib vs. diclofenac + 
PPI, using adverse event relative risks from the CONDOR trial, celecoxib has a cost of 
$3,707 and 8.805 QALYs while diclofenac + PPI has a cost of $3,757 and 8.813 QALYs. 
The incremental costs and QALYs of celecoxib vs. diclofenac + PPI are -$49.45 and 
-0.009 QALYs respectively. The incremental cost-effectiveness ratio for diclofenac 
+ PPI vs. celecoxib is $5,793. Drug costs account for 26% and 28% of the costs in 
the celecoxib and diclofenac + PPI arms, respectively. ConClusions: Celecoxib 
is a less costly alternative than diclofenac + PPI. The difference in QALYs between 
celecoxib and diclofenac + PPI is extremely small and through sensitivity analysis 
may not be significant.
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objeCtives: To estimate the 2-year cost per year in response of biologics for 
Rheumatoid Arthritis (RA) among US commercially insured adults. Methods: 
Adults (ages 18-63) newly initiating a biologic for RA (etanercept, abatacept, 
adalimumab, certolizumab, golimumab, and infliximab) were identified in the 
impairment (OWI) indexes. Additional questionnaires on patients’ characteristics 
and disease activity level, assessed on standardized scales: DAS28, PASI, CDAI, were 
added. Present economic activity (% of workers), presenteeism (time lost due to 
inefficient work), absenteeism (time of temporal absence caused by disease) and 
OWI ratios were calculated for each diagnostic group separately. Results: Of the 
three groups, patients with RA had the lowest rate of economic activity – 42%. 56% 
of CD patients and 57% of Ps patients worked for pay. Furthermore, productivity 
loss measured with OWI was highest in RA group: 43% of work time was lost. It was 
slightly better in CD and Ps groups, OWI amounted to 36% and 35% respectively. 
RA group had the highest absenteeism rate (18%) and also high presenteeism rate 
(27%), Ps group had the lowest absenteeism rate (9%) and the highest presenteeism 
rate (28%), CD group ranked between them with 16% absenteeism rate and 24% 
presenteeism rate. ConClusions: RA, CD and Ps all cause productivity loss, each 
in a different manner. M2W study is a unique national data source for indirect cost 
analysis for RA, CD and psoriasis.
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objeCtives: The aim of the study is to estimate the pension costs (social secu-
rity system in Italy is financed by public expenditure) induced by patients with 
musculoskeletal disorders (MD) and specifically for rheumatoid arthritis (RA), 
ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in Italy, between 2009 and 
2012. Methods: We analysed the database of National Institute of Social Security 
(INPS) for three types of social security benefits: disability benefits, disability pen-
sions (for people with reduced work ability) and incapacity pensions (for people 
without work ability). A probabilistic model with a Monte Carlo simulation was 
developed in order to estimate for MD, RA, AS and PsA, the total costs of the three 
types of benefits. For the estimation of the productivity loss for RA in the 2012, 
economic data (cost of work day) were collected from the databases of the National 
Institute of Statistics (ISTAT) and absenteism data from national literature review 
(Censis, Anmar, SIR, 2008; Leardini 2002; Salaffi 2005). Results: The model esti-
mated a total costs of € 311.534.554 ± € 31.849.117 in the 2009 and € 301.244.287 ± 
€ 33.871.230 in the 2012 for the disability benefits, € 11.163.392 ± € 3.047.946 in the 
2009 and € 10.560.086 ± € 3.079.987 in the 2012 for the incapacity pensions and 
€ 136.473.625 ± € 14.417.893 in the 2009 and € 123.608.660 ± € 13.734.418 in the 2012 
for the disability pensions. The productivity loss for RA in the 2012 amounted 
to € 1.145.377.593 ± € 100.396.928. ConClusions: The most important indirect 
costs in Italy in 2012 was represented by disability benefits (68% of the total cost), 
followed by disability pensions (30% of total indirect cost). A better prescription 
appropriateness and rapid access to innovative treatments (Italy, among the EU 
Countries, is the one with the greatest delay in access) would reduce the costs 
incurred by the social security system accompanied by an improvement on the 
effectiveness of interventions.
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objeCtives: We described the cost of the drug therapy for ankylosing spondylitis in 
the State of Minas Gerais, Brazil. Methods: We analysed data from the Outpatient 
Information System during March 2010 and February 2011 of the Brazilian Public 
Health System (SUS). We applied the probabilistic record linkage to match registers 
of the same patient and performed the analysis under the SUS’s perspective. We 
included patients over 18 years-old with diagnosis of ankylosing spondylitis who 
had begun the drug therapy after March 2010. We classified the patients in groups 
according to the initial therapy in anti-TNF agent users (infliximab, etanercept or 
adalimumab) or disease-modifying anti-rheumatic drugs-DMARD (the reference 
group). The cost was expressed in U.S. dollars. The analyses were performed with 
database manager system mysql and SPSS®19. Results: We indentified 236 anky-
losing spondylitis patients and 979 pharmacy claims. Mean age was 41.1 years 
(standard deviation 12.2) and most patients (70.0%) were men. Approximately 18% 
of patients withdrew the treatment. The total treatment expenditure in the study 
period was U$ 351,504.05; the cost with adalimumab represented 52.3% of this 
value. The estimated annual cost was U$ 117.53 for those who started sulfasala-
zine-DMARD treatment and ranged between U$ 3,251.08 and U$ 6,374.51 for anti-
TNF drugs. The median individual cost was U$ 2,553.90 for patients who initiated 
infliximab, U$ 2,516.44 for adalimumab, U$ 1,406.08 for etanercept and U$ 49.08 
for sulfasalazine-DMARD therapy. ConClusions: The cost of the anti-TNF agent 
treatment for ankylosing spondylitis is elevated. Therefore, the management of 
the public health system faces a challenge to offer an efficient and effectiveness 
patient care considering the limited public resources and the high demand for new 
health technologies.
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objeCtives: To investigate both clinical effects and costs of acupuncture under 
general medical practice for patients with chronic low back pain (CLBP) in 
Korea. Methods: A multicenter prospective observational study was performed. 
